...-dependent thalassaemia (NTDT) with iron excess during pre- and post-iron chelation. Methods: Subjects with NTDT, aged older than 10 years, with serum ferritin >300 ng/ml, were included. Iron chelation with deferasirox (10 mg/kg/day) was prescribed daily for 6 months. Results: Ten patients with a median...

...Duantida Songdej; Nongnuch Sirachainan; Pakawan Wongwerawattanakoon; Werasak Sasanakul; Praguywan Kadegasem; Witaya Sungkarat; Ampaiwan Chuansumrit Objective: To study the efficacy of combined treatment with oral and subcutaneous iron chelators. Material and Methods: 50-100 mg/kg/day of oral...

... and safety of oral iron chelators, and noninvasive techniques for the assessment of iron overload are translated into better patient outcomes. The construction of TM management guidelines facilitated the incorporation of such evidence into practice. However, as several aspects of the management of TM remain...

...M. Nagler; M. Gregor; W.A. Wuillemin We present 2 patients with hyperferritinemia, increased liver iron and hemochromatosis-associated HFE genotypes. At diagnosis, both patients had chronic anemia that prevented initiation of phlebotomy. Iron chelation with deferasirox proved to be a safe...

.... The aim of the present study was to investigate renal involvement in young thalassemia patients, using both conventional and early markers of renal dysfunction, and to correlate findings to iron chelation therapy. Forty-two patients aged 4–23 years were studied and, for analysis purposes, were divided...

... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Deferasirox Iron chelation Myelodysplastic syndrome Letter...

... to evaluate the time interval after which iron chelation becomes effective. In a first group of 19 children, treated intramuscularly with DFO at a dose of 20 mg/kg for 20 days a month, ferritin levels were followed for 739 days and a progressive increase with a significant linear correlation with time...

...Martin J. Pippard This paper reviews the factors governing the rate of iron loading and iron toxicity in the thalassaemia syndromes and sickle cell disease. It outlines the main determinants of iron mobilization by the iron-chelating drug, desferrioxamine, together with the effects of this drug...

... cardiac function. Original Papers Acta Haematol 1990:84:113-117 © I9 9 0 S . Karger AG. Basel 0001 -5 7 9 2 /9 0 /0 8 4 3 -0 113 $ 2.75/0 High Incidence of Cardiomyopathy in Beta-Thalassaemia Patients Receiving Regular Transfusion and Iron Chelation: Reversal by Intensified Chelation M.A. Aldouri3, B...

...F.N. Al-Refaie; P.A Veys; S. Wilkes; B. Wonke; A.V. Hoffbrand Agranulocytosis developed in a 20-year-old Greek patient with β-thalassaemia major, 11 weeks after commencing chelation with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (LI) and 6 weeks after receiving the drug at a total...

... with administration of the iron chelator. Retrospective studies in the children with cerebral malaria raised the possibility that, in addition to withholding iron from the parasite, desferrioxamine B may have enhanced the T helper 1 immune response and protected against iron-mediated peroxidant cerebral tissue damage...

..., an iron chelator, in reducing generation of these highly cytotoxic radical species. However, this biological demonstration has not been translated into improved postoperative patient outcome. 17 2 2009 © 1996 S. Karger AG, Basel 1996 Copyright / Drug Dosage / Disclaimer Copyright: All...

...Robert C. Hider; Roxana Choudhury; Bijaya L. Rai; Lotfollah S. Dehkordi; Surinder Singh Three parameters which are critical for the development of non-toxic orally active iron chelators are identified: bioavailability, selectivity for iron (III) and distribution and toxicity. Each is discussed...

... available for chelation therapy, e.g. oral once-daily administration of the iron chelator deferasirox. In 3 patients with MDS and 1 patient with PMF, deferasirox therapy resulted in an improvement in the hemoglobin level and a reduction in transfusion dependence. Our data open new insights regarding...

... overloaded patients. Blood 1998;91:295–300. 4. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998;339:417–423. 5. Taher A, Chamoun...

...A. Taher; E. Aoun; A.I. Sharara; F. Mourad; W. Gharzuddine; S. Koussa; A. Inati; A.P. Dhillon; A.V. Hoffbrand Twelve thalassaemia major patients have been given deferiprone 75 mg/kg body weight daily as iron chelation therapy for 5 years. Their ages ranged from 18 to 34 years (mean 24.2) at the end...

... not require stopping treatment. 22 7 1999 Desferrioxamine (DFX), the widely available iron-chelating drug has been shown to cause iron excretion sufficient to produce a negative iron balance in iron-loaded, transfusion-dependent patients. This has become the standard iron chelation therapy...